arrow
B

Bruce Cree

university of california
H指数:82
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neural autoantibodies in the cerebrospinal fluid of individuals with schizophrenia spectrum disorders

精神分裂症谱系障碍患者脑脊液中的神经自身抗体

2026-11-030
OAAI
Ocrelizumab treatment and disability progression in non-Hispanic Black and Hispanic or Latino individuals with relapsing multiple sclerosis: A post hoc analysis of the OPERA I and II trials

奥法他文治疗与非西班牙裔黑人及西班牙裔或拉丁裔复发性多发性硬化症患者残疾进展的关系:OPERA I和II试验的事后分析

2026-10-280
PRE
Development of a Diagnostic Autoantibody Assay to a Consensus Motif for the Risk Prediction of Epstein-Barr Virus-Related Multiple Sclerosis

针对Epstein-Barr病毒相关多发性硬化风险预测的共识基序诊断自身抗体检测方法的开发

2026-05-012
PRE
Diagnostic performance of central vein sign and paramagnetic rim lesion integration for multiple sclerosis

中央静脉征和顺磁性边缘病灶整合对多发性硬化的诊断性能

2026-04-200
PRE
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial

奥扎尼妥(ozanimod)在复发型多发性硬化中的长期安全性与有效性:DAYBREAK开放标签扩展试验的最终分析

2025-11-050
OA
Investigating the impact of age on neurodegeneration after optic neuritis in multiple sclerosis using optical coherence tomography

使用光学相干层析成像研究年龄对多发性硬化症中视神经炎后神经退行性变的影响

2025-10-210
OA
Myelin injury precedes axonal injury and symptomatic onset in multiple sclerosis

多发性硬化症的髓鞘损伤先于轴突损伤和症状发作

2025-10-200
PRE
Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials

奥扎尼妥单抗治疗复发型多发性硬化患者的脑萎缩及其与长期残疾和认知功能的关系:来自III期和开放标签扩展试验的结果

2025-07-230
PRE
High-Dose Pulse Glucocorticoid Treatment Prevents White Matter Spinal Cord Pseudoatrophy in Newly Diagnosed Multiple Sclerosis

大剂量脉冲糖皮质激素治疗可预防新诊断多发性硬化患者脊髓白质的假性萎缩

2025-06-240
OAAI